Cadence Reports Record $8.1 Billion Backlog and Lifts Full-Year Outlook
Cadence beats Q2 expectations with $2.11 EPS and $1.58B revenue.
Already have an account? Sign in.
Cadence beats Q2 expectations with $2.11 EPS and $1.58B revenue.
Xos secures its first U.S. Air Force contract to build a military-grade Xos Hub mobile charging system, marking its entry into defense.
Topline data from Amylyx’s Phase 3 LUCIDITY trial of avexitide for PBH arrives August 18. Prior results and unmet need fuel optimism.
4D Molecular gains support as B. Riley views EyePoint’s Phase 3 setback as favorable for its lead gene therapy candidate 4D-150.